Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Amar M Salam

Showing results (11-20 of 54) with videos related to

Pageof 6
Sort By:
Expert Review of Cardiovascular Therapy|December 19, 2012
Dronedarone in atrial fibrillation: the aftermath of the PALLAS trialAmar M Salam
Expert Opinion on Investigational Drugs|July 20, 2012
The therapeutic potential of PCSK9 inhibition in primary dyslipidemia, the example from SAR236553/REGN727Amar M Salam
Expert Opinion on Investigational Drugs|February 28, 2003
Expanding indications of statins; implications of the Heart Protection StudyAmar M Salam
Expert Opinion on Investigational Drugs|July 29, 2003
Selective aldosterone blockade with eplerenone in patients with congestive heart failureAmar M Salam
Expert Opinion on Investigational Drugs|June 4, 2004
Intensive lipid-lowering therapy in coronary artery disease: implications of the REVERSAL and PROVE-IT trialsAmar M Salam
Heart Views : the Official Journal of the Gulf Heart Association|March 10, 2021
Thrombosis Management and Challenges in COVID-19 Patients Presenting with Acute Coronary SyndromesRasha Kaddoura, Amar M Salam
Heart Views : the Official Journal of the Gulf Heart Association|March 10, 2021
Racing for COVID-19 Vaccine and Cure: Lessons and Tragedies in Human Subject ResearchAmar M Salam, Alison S Carr
Current Controlled Trials in Cardiovascular Medicine|January 25, 2002
Platelet glycoprotein IIb/IIIa receptor blockade in coronary artery diseaseJassim Al Suwaidi, Amar M Salam
Expert Opinion on Pharmacotherapy|July 15, 2005
Selected highlights from the 54th annual scientific session of the American College of Cardiology, Orlando, USA, 6-9 March 2005Amar M Salam, Jassim Al Suwaidi
Expert Opinion on Investigational Drugs|November 20, 2002
Platelet glycoprotein IIb/IIIa antagonists in clinical trials for the treatment of coronary artery diseaseAmar M Salam, Jassim Al Suwaidi
Pageof 6

Showing results (11-20 of 54) with videos related to

Sort By:
Pageof 6
Expert Review of Cardiovascular Therapy|December 19, 2012
Dronedarone in atrial fibrillation: the aftermath of the PALLAS trialAmar M Salam
Expert Opinion on Investigational Drugs|July 20, 2012
The therapeutic potential of PCSK9 inhibition in primary dyslipidemia, the example from SAR236553/REGN727Amar M Salam
Expert Opinion on Investigational Drugs|February 28, 2003
Expanding indications of statins; implications of the Heart Protection StudyAmar M Salam
Expert Opinion on Investigational Drugs|July 29, 2003
Selective aldosterone blockade with eplerenone in patients with congestive heart failureAmar M Salam
Expert Opinion on Investigational Drugs|June 4, 2004
Intensive lipid-lowering therapy in coronary artery disease: implications of the REVERSAL and PROVE-IT trialsAmar M Salam
Heart Views : the Official Journal of the Gulf Heart Association|March 10, 2021
Thrombosis Management and Challenges in COVID-19 Patients Presenting with Acute Coronary SyndromesRasha Kaddoura, Amar M Salam
Heart Views : the Official Journal of the Gulf Heart Association|March 10, 2021
Racing for COVID-19 Vaccine and Cure: Lessons and Tragedies in Human Subject ResearchAmar M Salam, Alison S Carr
Current Controlled Trials in Cardiovascular Medicine|January 25, 2002
Platelet glycoprotein IIb/IIIa receptor blockade in coronary artery diseaseJassim Al Suwaidi, Amar M Salam
Expert Opinion on Pharmacotherapy|July 15, 2005
Selected highlights from the 54th annual scientific session of the American College of Cardiology, Orlando, USA, 6-9 March 2005Amar M Salam, Jassim Al Suwaidi
Expert Opinion on Investigational Drugs|November 20, 2002
Platelet glycoprotein IIb/IIIa antagonists in clinical trials for the treatment of coronary artery diseaseAmar M Salam, Jassim Al Suwaidi
Pageof 6